Colorectal Cancer

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the surgical barriers in treating patients with colorectal cancer that has metastasized outside of the liver.

Thierry Andre, MD, professor of medical oncology, University Pierre et Marie Curie (UMPC), and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses the results of the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.

Data from the CheckMate-142 study support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for the treatment of patients with previously treated DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses nivolumab (Opdivo) in patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic CRC.

Older patients with colorectal cancer are more likely to develop cardiovascular disease and congestive heart failure, according to results from an analysis of the SEER database.

Combining the investigational oral cancer stem cell pathway inhibitor napabucasin with the PD-1 inhibitor pembrolizumab showed a signal of efficacy in the first 8 patients enrolled in a multicenter phase I/II trial of patients with metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the quality of life findings for a dose-escalation study of regorafenib (Stivarga) in metastatic colorectal cancer.

The combination of cetuximab and pembrolizumab was found to be well tolerated in patients with RAS wild-type metastatic colorectal cancer.

Sequencing regorafenib before cetuximab showed superior overall survival compared with the reverse sequence in patients with metastatic colorectal cancer following failure of standard chemotherapy.

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the updated findings from CheckMate-142 in metastatic colorectal cancer during the 2018 Gastrointestinal Cancers Symposium.

Tanios Bekaii-Saab, MD, discusses the results and significance of the ReDOS study in metastatic colorectal cancer, as well as shared some insight on the Reverce trial.

Leonard Saltz, MD, executive director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses the option of FOLFIRINOX for the treatment of patients with metastatic colorectal cancer.

TAS-102 improved overall survival compared with placebo in previously treated Asian patients with metastatic colorectal cancer (mCRC).

John L. Marshall, MD, recaps some of the biggest CRC advancements of 2017, and explains what those successes mean for the treatment paradigm moving forward.

Nancy E. Kemeny, MD, discusses the combination of pump and systemic therapy as a liver-directed treatment option for patients with metastatic colorectal cancer.

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing trials investigating treatment for patients with BRAF-mutant colorectal cancer (CRC).

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses frontline treatment options for patients with colorectal cancer (CRC).

Leonard Saltz, MD, discusses current go-to therapies and overarching questions for mCRC treatment.

William R. Jarnagin, MD, discusses the necessary role of surgery and novel techniques in patients with colorectal cancer.

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses pembrolizumab (Keytruda) in colorectal cancer.

Nancy E. Kemeny, MD, a medical oncologist at Memorial Sloan Kettering Cancer Institute, discusses liver-directed therapies for patients with metastatic colorectal cancer (CRC).

Shubham Pant, MD, stresses the importance of clinical trials as an avenue to establish more novel treatment decisions in colorectal cancer.

Mutations in the BRAF kinase are found in a relatively small number of patients with metastatic colorectal cancer, but they nonetheless have important implications for prognosis and response to standard therapy.

Leonard Saltz, MD, Executive Director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses chemotherapy for patients with metastatic colorectal cancer.